RNAZHealthcare · BiotechnologyRNAZ Stock Forecast: TransCode Therapeutics, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 1 Aug 2026 — in the lower half.
RNAZ stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores TransCode Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (96): Smaller than most of the companies we track.
Momentum (20): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own TransCode Therapeutics, Inc. — and when they’d sell — is the membership.
RNAZ stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on RNAZ, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Apr 2025 | HC Wainwright & Co. | Maintains | Buy | $20 → $10 |
| 13 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Dec 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 29 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 Apr 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Apr 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Oct 2023 | HC Wainwright & Co. | Reiterates | Buy | $3.00 |
| 15 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | $12 |
| 15 Nov 2022 | HC Wainwright & Co. | Maintains | Buy | $10 → $6.00 |
| 7 June 2022 | HC Wainwright & Co. | Initiates | Buy | $10 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
RNAZ analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
TransCode Therapeutics, Inc. (RNAZ) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.0×
- Price / sales
- —
- Price / book
- 3.3×
- EV / EBITDA
- −5.8×
Cheaper than 75% of US stocks
Cheaper than 31% of US stocks
Cheaper than 80% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- −52.1%
- Return on assets
- −17.1%
- Dividend yield
- —
Higher than 21% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
RNAZ vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RNAZ appears on the weeks it earns a place.
Frequently asked questions about RNAZ stock
Is RNAZ stock a buy right now?
Of the 1 analysts covering TransCode Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks TransCode Therapeutics, Inc. 27 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank RNAZ?
As at 1 Aug 2026, TransCode Therapeutics, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).
What is the RNAZ stock forecast for 2030?
No analyst covering TransCode Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RNAZ are extrapolating price history, which says nothing about the business.
What does TransCode Therapeutics, Inc. do?
Transcode Therapeutics Inc. is a biotechnology company focused on leveraging RNA-based technologies for the treatment of cancer.
About TransCode Therapeutics, Inc.
Transcode Therapeutics Inc. is a biotechnology company focused on leveraging RNA-based technologies for the treatment of cancer. Its primary function is to develop innovative therapeutics aimed at overcoming limitations in traditional cancer treatments by utilizing the precision of RNA-targeted approaches. Transcode's platform is poised to address various cancer types, particularly those with poorly met medical needs, by delivering RNA molecules directly to cancer cells, potentially minimizing side effects commonly associated with broader-acting chemotherapies. Transcode Therapeutics is significantly impacting the healthcare sector, particularly within oncology, by pioneering RNA therapeutics that could redefine cancer treatment paradigms. The company's research and development efforts are crucial in the biopharmaceutical landscape as RNA-based therapies represent a burgeoning field with the potential to offer more personalized and effective cancer care options. By advancing novel therapies, Transcode Therapeutics plays a significant role in transforming the oncology treatment landscape and exemplifies the innovation driving advancements in modern medicine. Its focus on RNA technology underscores the growing importance of genetic and molecular sciences in developing next-generation medical solutions.
CEO Dr. Philippe P. Calais Ph.D., Pharm., Pharm.D. · 12 employees · United States · https://www.transcodetherapeutics.com